Vasopressin & Oxytocin in Control of the Cardiovascular System: An Updated Review

被引：38

作者：

Japundzic-Zigon, Nina ^{[1
]}

Lozic, Maja ^{[1
]}

Sarenac, Olivera ^{[1
]}

Murphy, David ^{[2
]}

机构：

[1] Univ Belgrade, Fac Med, Dr Subotica 1, Belgrade 11000, Serbia

[2] Univ Bristol, Sch Clin Sci, Bristol, Avon, England

来源：

CURRENT NEUROPHARMACOLOGY | 2020年 / 18卷 / 01期

关键词：

Vasopressin; oxytocin; blood pressure; heart rate; short-term variability; stress; hypertension; heart failure; PARAVENTRICULO-SPINAL NEURONS; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC PREGANGLIONIC NEURONS; ROSTRAL VENTROLATERAL MEDULLA; ATRIAL-NATRIURETIC-PEPTIDE; MESSENGER-RIBONUCLEIC-ACID; V-1B RECEPTOR ANTAGONIST; PITUITARY-ADRENAL AXIS; BLOOD-PRESSURE; ARGININE-VASOPRESSIN;

D O I：

10.2174/1570159X17666190717150501

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Since the discovery of vasopressin (VP) and oxytocin (OT) in 1953, considerable knowledge has been gathered about their roles in cardiovascular homeostasis. Unraveling VP vasoconstrictor properties and V1a receptors in blood vessels generated powerful hemostatic drugs and drugs effective in the treatment of certain forms of circulatory collapse (shock). Recognition of the key role of VP in water balance via renal V2 receptors gave birth to aquaretic drugs found to be useful in advanced stages of congestive heart failure. There are still unexplored actions of VP and OT on the cardiovascular system, both at the periphery and in the brain that may open new venues in treatment of cardiovascular diseases. After a brief overview on VP, OT and their peripheral action on the cardiovascular system, this review focuses on newly discovered hypothalamic mechanisms involved in neurogenic control of the circulation in stress and disease.

引用

页码：14 / 33

页数：20

共 268 条

[1] *LA STRUCTURE DE LA VASOPRESSINE DE BOEUF [J].

ACHER, R ;

CHAUVET, J .

BIOCHIMICA ET BIOPHYSICA ACTA, 1953, 12 (03) :487-488

[2] NITRIC-OXIDE MAY PARTICIPATE IN V-2 VASOPRESSIN-RECEPTOR-MEDIATED RENAL VASODILATION [J].

AKI, Y ;

TAMAKI, T ;

KIYOMOTO, H ;

HE, H ;

YOSHIDA, H ;

IWAO, H ;

ABE, Y .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1994, 23 (02) :331-336

[3] Responses to laboratory psychosocial stress in postpartum women [J].

Altemus, M ;

Redwine, LS ;

Leong, YM ;

Frye, CA ;

Porges, SW ;

Carter, CS .

PSYCHOSOMATIC MEDICINE, 2001, 63 (05) :814-821

[4]

ALTURA BM, 1984, FED PROC, V43, P80

[5] Osmoregulatory control of renal sodium excretion after sodium loading in humans [J].

Andersen, LJ ;

Norsk, P ;

Johansen, LB ;

Christensen, F ;

Engstrom, T ;

Bie, P .

AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1998, 275 (06) :R1833-R1842

[6] Efficacy and Safety of Oral Conivaptan, a Vasopressin-Receptor Antagonist, Evaluated in a Randomized, Controlled Trial in Patients With Euvolemic or Hypervolemic Hyponatremia [J].

Annane, Djillali ;

Decaux, Guy ;

Smith, Neila .

AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2009, 337 (01) :28-36

[7] Vasopressin regulation of blood pressure and volume: findings from V1a receptor-deficient mice [J].

Aoyagi, Toshinori ;

Koshimizu, Taka-aki ;

Tanoue, Akito .

KIDNEY INTERNATIONAL, 2009, 76 (10) :1035-1039

[8] ROLE OF ARGININE-VASOPRESSIN FOR THE DEVELOPMENT OF HYPERTENSION FOLLOWING AORTIC CONSTRICTION [J].

APERIA, A ;

SAHLGREN, B ;

EKLOF, AC ;

LUNDIN, S ;

MELIN, P .

ACTA PHYSIOLOGICA SCANDINAVICA, 1986, 128 (04) :495-499

[9] Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects [J].

Bankir, L .

CARDIOVASCULAR RESEARCH, 2001, 51 (03) :372-390

[10] Structural bases of vasopressin/oxytocin receptor function [J].

Barberis, C ;

Mouillac, B ;

Durroux, T .

JOURNAL OF ENDOCRINOLOGY, 1998, 156 (02) :223-229

← 1 2 3 4 5 6 7 8 9 10 →